638033

To:	(10)(2e)	[(10)(2e)	@rivm.nl];	(10)(2e)	[(10)(2e)	@rivm.nl]
From:	(10)(2e)							
Sent:	Fri 9/25/20	20 10:	27:56 AM	1				
Subject:	RE: PCR d	lata FF	X deel 1					
Received:		Fri 9/2	5/2020 10	0:27:56 AM				

Ab levels is in de file in sent you.

 From:
 (10)(2e)
 @rivm.nl>

 Sent:
 vrijdag 25 september 2020 09:20

 To:
 (10)(2e)
 @rivm.nl>;
 (10)(2e)
 @rivm.nl>

 Subject:
 Re:
 PCR data FFX deel 1
 1

Hi both,

I can do the groups based on NP/OP/Feces. Thank you very much I will start the analysis when the course I am taking is over. When the rest of the data is ready (Ab levels, disease scores etc) please let me know so I can also append it! I will keep you updated. I

Best,

(10)(2e)
From: (10)(2e) Sent: Thursday, 24 September 2020 13:47:05 To: (10)(2e) Gubject: RE: PCR data FFX deel 1
Wonderful! PCR data on NP/OP and feces will do for now, am I right (1912) Many thanks (10)(2e)
BW, (10)(2e)
From: (10)(2e) @rivm.nl> Sent: donderdag 24 september 2020 13:30 To: (10)(2e) (10)(2e) @rivm.nl>; Subject: RE: PCR data FFX deel 1
Hoi (10)(20) This is de list with most recent PCR data that I have. Some saliva data are still missing but he NP/OP and faces data should be complete. We are doing some final checks on the day of onset of symptoms datasets. Let me know if you need this data set as well. Groeten, (10)(2e)
From: (10)(2e) (10)(2e) @rivm.n > Sent: dinsdag 22 september 2020 09:14 To: (10)(2e) (10)(2e) (10)(2e) (10)(2e) Subject: PCR data FFX deel 1
Hoi (10)(2e)
(10)(2e) wil de definitieve analyses op TruCount data van FFX deel 1 gaan afronden, zodat we dit snel kunnen

opschrijven. Is er inmiddels al een definitieve versie van de PCR data?

Groet (10)(2e)

 From:
 (10)(2e)
 < (10)(2e)</th>
 @rivm.nl>

 Sent:
 donderdag
 20 augustus
 2020
 13:16

 To:
 (10)(2e)
 < (10)(2e)</td>
 @rivm.nl>

 Cc:
 (10)(2e)
 < (10)(2e)</td>
 @rivm.nl>

Subject: RE: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)

Hi (10)(2e)

See my reply in blue.

I added the file where I made groups based on PCR and symptom data. Again this is not the definitive list yet but might be of help.

10	11	(2	6	
<u>u</u> .	20	1	Ξ.	

 From:
 (10)(2e)

 (10)(2e)
 @rivm.nl>

 Sent:
 donderdag
 6 augustus
 2020
 08:45

 To:
 (10)(2e)

 (10)(2e)
 @rivm.nl>

 Cc:
 (10)(2e)

 (10)(2e)
 @rivm.nl>;

Subject: FW: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)

Hi,

I think, it is good to understand/solve the observed discrepancies (in PCR+/- listing) and to discuss this soon, to be able to complete the sample selection for cellular immunity testing (I will be here coming Monday and Tuesday before my Holidays)

Groetjes	,
(10)(20)	

From: (10)(2e)

Sent: donderdag 6 augustus 2020 08:38 To: (10)(2e) < (10)(2e) @rivm.nl>

Subject: RE: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)

Hi (10)(2e)

Unfortunately, I received just prior to (10)(2e) Holidays a few files with FFX data from her (without any explanation). I do not have access to any other FFX data.

See my response (in red) in your request in mail below.



Fro	<mark>m:</mark> (10)(2	e) <	(10)(2e) <u>@rivm.nl</u> >
Senta	woensdag	5 augu	stus 2020	12:06
To:	(10)(2e)	< (10)(2e)	@rivm.nl>

Subject: RE: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)



I have a question regarding the list of donors you sent. Since there was no nasal or oral swabs for T3 samples, for me it was not really clear what to call PCR+ and PCR-.

I assume you called them PCR+ if there is a + PCR result for any sample in any timepoint (feces,nasal,oral,...) is that correct? In the list there are also t=1 Ab, t=2 Ab and t=3 Ab. Are these the results of the antibody data

(which I do not have so I couldn't cross check)? I have received a few files from (10)(2e) ust before her Holidays without any explanation, she made lists of PCR+ and PCR- persons. I indeed assume that she did that based on the criteria you mention above, but unfortunately I have no definite information from her on that. I added the antibody data in the list, according to the Wantai data that I also received from a different file with serology data of (1) (just extra information for a good sample selection).

PCR+ indeed is based on a positive PCR at some point in the study. Some of the index cases were never tested positive in the study but were of course positive before study entry.

There is a file containing Wantai, microarray and MIA serology data which is currently being checked and completed.

I made the news groups as I explained to you in my last email and there was something I couldn't figure out. For example, for donor 72 who was a hospitalized person positive for Abs in all timepoint, PCR excel sheet (attached image) had no + values. Donor 12 (PCR+ without symptoms) is not PCR+ in the PCR data I obtained either. I am afraid, I can not help you with this, since (10)(2e) made the lists with PCR+ and PCR-, from which I selected the samples. I think we should discuss this with (10)(2e) (she will be here Monday 10th August, I think). I also found some discrepancies in data between the different files that I want to understand (although these discrepancies I found were only from participants from which I did not select any samples), but I do not have access to the (original) raw data.

Participant 72 is an index case so already had a positive PCR before study entry. Participant 12 had a positive PCR at Day12 (sample D). Some of the participants had additional NP/OP collections at day 3, 6, 9 and/or 12.

Therefore, I cannot really make groups at this point for the export. Do you have any idea what's going on? I believe the PCR export you had may be more complete than the one I had. Would it be an idea to use the same excel sheets for Age, symptoms, Ab status etc for the analysis so we do not run into these kind of problems?

447410T	34	NUM	HHJH/VII	v		C.PC
4490721	33	volwassen	44907211			
4490722	33	volwassen	44907221	0		0
4490723	33	volwassen	44907231			
4490731	22	volwassen	44907311	0		0

Kind regards,

From: (10)(2e) < (10)(2e) @rivm.nl>

Sent: vrijdag 31 juli 2020 13:38

To: (10)(2e) < (10)(2e) @rivm.nl>

Subject: RE: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)



Thanks, it would be interesting to see the data on (direct) immune phenotyping for these 6 groups. Perhaps, you can also mark the 7 participants that went to the hospital because of COVID-19 (see also Table below hospitalization 'ja').



From: (10)(2e) < (10)(2e) @rivm.nl> Sent: vrijdag 31 juli 2020 13:31 To: (10)(2e) < (10)(2e) @rivm.nl>

Subject: RE: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)

Hi (10)(2e)

Thanks for the list of the selected samples. I will provide the excel sheet but I can also make some figures. I thought I could do 6 groups and make barplots for each subset (including cell numbers and percentages). This would give us a clear image I believe comparing adults/kids/asymptotic/symptotic in one figure.

638033

-PCR- adults -PCR+ adults with symptoms -PCR+ adults without symptoms -PCR+ kids -PCR+ kids with symptoms -PCR+ kids without symptoms

If you would like to add anything please let me know, otherwise I will export these information and upload the data on the FFX folder next week and let everyone know.

Groetjes,
(10)(2e)
From: (10)(2e) < (10)(2e) @rivm.nl>
Sent: donderdag 30 juli 2020 12:57
To: (10)(2e) < (10)(2e) @rivm.n[>; (10)(2e) < (10)(2e) @rivm.n[>; (10)(2e)
< (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e)
< (10)(2e) @rivm.nl>; (10)(2e) < (10)(2e) @rivm.nl>; (10)(2e) //(0.2e) (10)(2e) //(0.2e) //(0
< (10)(2e) @rivm.nl>

Subject: FFX sample selection for cellular immunity: proposal (incl. phenotyping, innate immunity, T cell immunity assays)

Dear all,

The Table with FFX selected samples:

Selection	FFX sam	ples								Not hospitalized: n		
										Hospitalized: n=3N	1, n=4F	
PCR+ kids			n=19	PCR+ ad	ults with sy			n=23				
ID	t=1 Ab	t=2 Ab	t=3 Ab	ID	t=1 Ab	t=2 Ab	t=3 Ab	hospital	age (y)	time after symptom	discrepanc	e diagn (
	no serum			<u>44,9088</u> 8	2	<u>,00</u> 8	<u>,008</u>	ja -	54	include anyway	hosp	
449450	no serum			449109	pes	pos		ja	40	include anyway	hosp	
449506	neg		pos	449072	<i>pos</i>	pas	<u>pa</u> s	ja .	44	include anyway	hosp	
449476	pos			<u>449063</u>	001	pas	002	ja .	42	include anyway	hosp	
449481	neg	pos		449070	<u>00</u> 1	008	002	ja -	46	include anyway	hosp	
449461	pos	pos		449010	<i>pos</i>	pas	pas	ja.	49	include anyway	hosp	
449451	pos	pos		449009	<u>00</u> 1	pas	002	ja -	52	include anyway	hosp	
449452	pos	pos		<u>449071</u>	001	005	002	nee	45	140	<u>10</u>	
449498	pos	pos		449062	<i>pas</i>	pas	<i>00\$</i>	nee	48	140	<i>119</i>	
449485	pos	pos	pos	<u> 449006</u>	neg	pas	008	nee	13	140	<i>110</i>	
449497	pos	pos		<u> 119017</u>	neg	pas	002	nee	10	131	<u>110</u>	
449499	neg	pos		449058	001	008	002	acc.	31	1.30	9C8	13d -> •
449460	008	DOS		449008	neg	005	001	nee	47	130	119	
449513	008	DOS	003	449065	001		002	nee	19	131	110	
449490	neg	DOS		449094	pas	pas	pos	nee	43	13d	528	13d -> -
449475	DOS	DOS		449053	001	005	005	nee	57	130	119	
449448	neg	DOS		449041	001	Das	002	Dec	11	120	110	
449463	DOS	200	DOS	449087	001	pos	002	nee	88	11d	10	
449471	pas	005	pas	449074		005	005	nee	18	11d	19	
			-	449092	001	203	205	nee	18	110	119	
				449114	<i><u></u></i> <u></u>	203	208	000	32	110	119	
				449122	201	205		nee	52	100	125	10d -> -
					neg	205	<u>00</u> 2	065	42	100	228	10d -> -
												100.0
PCB+ kids	s without	symptoms	n=16	PCR+ add	ilts withou	t sympton	ns n=6			-		
	t=1 Ab	t=2 Ab	t=3 Ab	ID	t=1 Ab	t=2 Ab	t=3 Ab					
449447		1		449046	pes	2	008			female		
	no serum			449107	pes	205	D03			male		
	no serum			449019	neg	neg	neg			PBMCs >= 2 vials f	or	t=1
449512	neg				nea/aas	205	205					t=2
449458	neg	no serum		119020	neg	208 208	208					t-3
449442	neg	DOS	DOS	149012	neg	neg	neg					
449505	neg	DOS	pos	378876	. And y	1.60	200gs					
449504	neg	pos	100s									
449486	pos	pos					_	-				
449487	pos	pos				-		_	-			
449480	neq	pos						-				
449427		pos	DOS									
449441	neg		pos									
449446	neg	pos	hos									
449407	neg	DOS						-				
449474	neg	neg										
4939/4	pos	pos	T									
(10)(2e) (10)(2e)	("best ro (10)(20)	egards"*)				I	1		1		

Centrum voor Immunologie van Infectieziekten en Vaccins (IIV) Centrum voor Infectieziektebestrijding (Cib) Rijksinstituut voor Volksgezondheid en Milieu (RIVM) A. van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | Kamer (10)(2e) Postbus 1 | 3720 BA | Bilthoven

.....

T +31 (10)(2e) E (10)(2e) <u>@rivm.nl</u> I <u>www.rivm.nl</u>

Aanwezig o